Related Experiment Video
Updated: Jul 10, 2026
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi
Mohammad Rashel1, Jumpei Uchiyama, Takako Ujihara
1Department of Biochemistry, Kochi Medical School, Nankoku 783-8505, Japan.
Abstract:
We report the successful purification of a cloned lysin encoded by the novel Staphylococcus aureus bacteriophage phi MR11. The lysin, designated MV-L, rapidly and completely lysed cells of a number of S. aureus strains tested, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant S. aureus and a subset of vancomycin-intermediate S. aureus (VISA) in growing conditions. MV-L-mediated killing is specific to S. aureus and not to other species, except for S. simulans. MV-L exerted its staphylocidal effect synergistically with glycopeptide antibiotics against VISA. MV-L efficiently eliminated MRSA that had been artificially inoculated into the nares of mice. The intraperitoneal administration of MV-L also protected mice against MRSA septic death, without any harmful effects. Although MV-L evoked detectable levels of a humoral response in mice, the antibodies did not abolish the bacteriolytic activity. These results indicate that MV-L might be useful as a powerful therapeutic agent against multidrug-resistant S. aureus infections.
Insights
A novel lysin, MV-L, effectively targets and eliminates various Staphylococcus aureus strains, including drug-resistant forms. This discovery offers a promising new therapeutic agent for multidrug-resistant Staphylococcus aureus infections.
Area of Science:
- Microbiology
- Molecular Biology
- Infectious Diseases
Background:
- The rise of multidrug-resistant Staphylococcus aureus (MRSA) necessitates novel therapeutic strategies.
- Bacteriophage-derived lysins represent a promising class of antimicrobial agents.
Purpose of the Study:
- To purify and characterize a cloned lysin, MV-L, from Staphylococcus aureus bacteriophage phi MR11.
- To evaluate the efficacy of MV-L against various Staphylococcus aureus strains, including resistant variants.
- To assess the therapeutic potential of MV-L in a murine model of MRSA infection.
Main Methods:
- Purification of cloned lysin MV-L.
- In vitro lysis assays against diverse Staphylococcus aureus strains (MRSA, VISA, vancomycin-resistant S. aureus).
- Synergy testing with glycopeptide antibiotics.
- In vivo efficacy studies in murine models (nasal colonization and septicemia).
Main Results:
- MV-L rapidly and completely lysed multiple Staphylococcus aureus strains, including MRSA and vancomycin-resistant strains.
- MV-L demonstrated synergistic activity with glycopeptide antibiotics against vancomycin-intermediate S. aureus (VISA).
- MV-L effectively cleared MRSA nasal colonization and protected mice against MRSA septic death with no observed toxicity.
Conclusions:
- The purified lysin MV-L exhibits potent bacteriolytic activity against a broad spectrum of Staphylococcus aureus, including multidrug-resistant strains.
- MV-L demonstrates significant therapeutic potential as a standalone agent and in combination therapy for MRSA infections.
- MV-L represents a promising candidate for developing novel treatments against challenging Staphylococcus aureus infections.
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:30Lytic Cycle of Bacteriophages
02:53CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
01:26DNA Bacteriophages